Lv3
380 积分 2023-04-21 加入
High Efficacy and Low Toxicity of MB-106, a Third Generation CD20 Targeted CAR-T for Treatment of Relapsed/Refractory B-NHL and CLL
2小时前
待确认
Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation Study in Ibaraki Group (ATTENTION-IBARAKI)
7个月前
已关闭
Bevacizumab in advanced lung cancer: state of the art
7个月前
已完结
Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation
9个月前
已完结
Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma
9个月前
已完结
ITAM‐based receptors in natural killer cells
10个月前
已完结
294 Comparison of preclinical efficacy between CD19 CAR-T and CD3×CD19 bispecific antibody (blinatumomab)
1年前
已完结
ATG-101, a tetravalent PD-L1×4-1BB bispecific antibody, augments anti-tumor immunity through PD-L1 blockade and PD-L1-directed 4-1BB activation
1年前
已完结
皖公网安备34019202002308
